HDM1005
Phase Ia Clinical Study of HDM1005 Injection
Huadong Medicine · Phase 1 · Completed · Enrollment 65
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| HDM1005 injection dose level 1 | n/r | n/r | n/r | n/r |
| HDM1005 injection dose level 2 | n/r | n/r | n/r | n/r |
| HDM1005 injection dose level 3 | n/r | n/r | n/r | n/r |
| HDM1005 injection dose level 4 | n/r | n/r | n/r | n/r |
| HDM1005 injection dose level 5 | n/r | n/r | n/r | n/r |
| HDM1005 injection dose level 6 | n/r | n/r | n/r | n/r |
| HDM1005 injection dose level 7 | n/r | n/r | n/r | n/r |
Not shown
- HDM1005 injection dose level 1: endpoint not reported
- HDM1005 injection dose level 2: endpoint not reported
- HDM1005 injection dose level 3: endpoint not reported
- HDM1005 injection dose level 4: endpoint not reported
- HDM1005 injection dose level 5: endpoint not reported
- HDM1005 injection dose level 6: endpoint not reported
- HDM1005 injection dose level 7: endpoint not reported